Johnson & Johnson’s Phase 3 MajesTEC-3 study shows that the combination of teclistamab and subcutaneous daratumumab (tec+dara) significantly improves outcomes for relapsed or refractory multiple myeloma...
AbbVie and Simcere Zaiming announced a licensing option agreement to develop SIM0500, a trispecific antibody targeting multiple myeloma. Currently in Phase I trials, SIM0500 induces strong...
Immuno-oncology and molecular oncology are two of Sanofi's most promising bets to tackle some of the most difficult-to-treat cancers. While immuno-oncology research is focused on finding...
Hemogenyx Pharmaceuticals Ltd. will start trading on the London Stock Exchange under the ticker symbol HEMO on Thursday, October 5, 2017.